Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol

Go Makimoto; Eiki Ichihara; Katsuyuki Hotta; Kiichiro Ninomiya; Isao Oze; Daisuke Minami; Takashi Ninomiya; Toshio Kubo; Kadoaki Ohashi; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura

Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol

Go Makimoto, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Isao Oze, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Kadoaki Ohashi, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

Original language	English
Pages (from-to)	319-323
Number of pages	5
Journal	Acta medica Okayama
Volume	72
Issue number	3
Publication status	Published - 2018

Keywords

Cisplatin
Furosemide
Hydration
Lung cancer
Mannitol
Non-small cell lung cancer

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Fingerprint

Dive into the research topics of 'Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol'. Together they form a unique fingerprint.

Cite this

Makimoto, G., Ichihara, E., Hotta, K., Ninomiya, K., Oze, I., Minami, D., Ninomiya, T., Kubo, T., Ohashi, K., Tabata, M., Maeda, Y., & Kiura, K. (2018). Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol. Acta medica Okayama, 72(3), 319-323.

Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol. / Makimoto, Go ; Ichihara, Eiki ; Hotta, Katsuyuki et al.
In: Acta medica Okayama, Vol. 72, No. 3, 2018, p. 319-323.

Research output: Contribution to journal › Article › peer-review

Makimoto, G , Ichihara, E , Hotta, K , Ninomiya, K, Oze, I, Minami, D, Ninomiya, T, Kubo, T, Ohashi, K , Tabata, M , Maeda, Y & Kiura, K 2018, 'Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol', Acta medica Okayama, vol. 72, no. 3, pp. 319-323.

@article{f9beefd6dfa0453f96ddbdbf6b9d1a40,

title = "Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol",

abstract = "Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.",

keywords = "Cisplatin, Furosemide, Hydration, Lung cancer, Mannitol, Non-small cell lung cancer",

author = "Go Makimoto and Eiki Ichihara and Katsuyuki Hotta and Kiichiro Ninomiya and Isao Oze and Daisuke Minami and Takashi Ninomiya and Toshio Kubo and Kadoaki Ohashi and Masahiro Tabata and Yoshinobu Maeda and Katsuyuki Kiura",

note = "Funding Information: This study will be conducted with support from the Center for Innovative Clinical Medicine, Okayama University Hospital. We thank the study coordinator and all of the other investigators at Okayama University Hospital who made this study possible: Masamoto Nakanishi, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Kazuya Nishii, Naohiro Oda, and Yousuke Toyota. Publisher Copyright: {\textcopyright} 2018 by Okayama University Medical School.",

year = "2018",

language = "English",

volume = "72",

pages = "319--323",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "3",

}

TY - JOUR

T1 - Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer

T2 - The OLCSG1406 study protocol

AU - Makimoto, Go

AU - Ichihara, Eiki

AU - Hotta, Katsuyuki

AU - Ninomiya, Kiichiro

AU - Oze, Isao

AU - Minami, Daisuke

AU - Ninomiya, Takashi

AU - Kubo, Toshio

AU - Ohashi, Kadoaki

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

AU - Kiura, Katsuyuki

N1 - Funding Information: This study will be conducted with support from the Center for Innovative Clinical Medicine, Okayama University Hospital. We thank the study coordinator and all of the other investigators at Okayama University Hospital who made this study possible: Masamoto Nakanishi, Hirohisa Kano, Hiromi Watanabe, Yusuke Hata, Kazuya Nishii, Naohiro Oda, and Yousuke Toyota. Publisher Copyright: © 2018 by Okayama University Medical School.

PY - 2018

Y1 - 2018

N2 - Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

AB - Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.

KW - Cisplatin

KW - Furosemide

KW - Hydration

KW - Lung cancer

KW - Mannitol

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85048880341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048880341&partnerID=8YFLogxK

M3 - Article

C2 - 29926012

AN - SCOPUS:85048880341

SN - 0386-300X

VL - 72

SP - 319

EP - 323

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 3

ER -

Randomized phase II study comparing mannitol with furosemide for the prevention of renal Toxicity induced by cisplatin-based chemotherapy with short-term low-volume hydration in advanced non-small cell lung cancer: The OLCSG1406 study protocol

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this